<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        52-116-99
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CURAM 156.25MG-5ML POWDER FOR SUSP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMOXICILLIN,CLAVULANIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125,31.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANDOZ" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Curam&reg; is an antibiotic and works by killing bacteria that cause infections. It contains two different medicines called amoxicillin and clavulanic acid. Amoxicillin belongs to a group of medicines called &ldquo;penicillins&rdquo; that can sometimes be stopped from working (made inactive). The other active component (clavulanic acid) stops this from happening.</p><p>&nbsp;</p><p>Curam&reg; is used in adults and children to treat the following infections:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; middle ear and sinus infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin and soft tissue infections including dental infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone and joint infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not give your child Curam&reg; :</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they are allergic to amoxicillin, clavulanic acid, penicillin or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have ever had a severe allergic reaction to any other antibiotic. This can include a skin rash or swelling of the face or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if they have ever had liver problems or jaundice (yellowing of the skin) when taking an antibiotic.</p><p>&nbsp;</p><p><strong>Do not give Curam&reg; to your child if any of the above apply to your child. </strong>If you are not sure, talk to your doctor or pharmacist before giving Curam&reg;.</p><p>&nbsp;</p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist before giving your child this medicine if they:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have glandular fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are being treated for liver or kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are not passing water regularly.</p><p>If you are not sure if any of the above apply to your child, talk to their doctor or pharmacist before giving Curam&reg;.</p><p>In some cases, your doctor may investigate the type of bacteria that is causing your child&rsquo;s infection. Depending on the results, your child may be given a different strength of Curam&reg; or a different medicine.</p><p><strong>Conditions you need to look out for</strong></p><p>Curam&reg;can make some existing conditions worse, or cause serious side effects. These include allergic reactions, convulsions (fits) and inflammation of the large intestine. You must look out for certain symptoms while your child is taking Curam&reg;, to reduce the risk of any problems. See &lsquo;<em>Conditions you need to look out for&rsquo; </em>in <strong>Section 4</strong>.</p><p><strong>Blood and urine tests</strong></p><p>If your child is having blood tests (such as red blood cell status tests or liver function tests) or urine tests (for glucose), let the doctor or nurse know that they are taking Curam&reg;. This is because Curam&reg; can affect the results of these types of tests.</p><p>&nbsp;</p><p><strong>Other medicines and Curam&reg;</strong></p><p>Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines. This includes medicines that can be bought without a prescription and herbal medicines.</p><p>If your child is taking <strong>allopurinol </strong>(used for gout) with [nationally completed name], it may be more likely that they will have an allergic skin reaction.</p><p>&nbsp;</p><p>&nbsp;</p><p>If your child is taking <strong>probenecid </strong>(used for gout), your doctor may decide to adjust your dose of [nationally completed name].</p><p>If medicines to help stop blood clots (such as <strong>warfarin</strong>) are taken with Curam&reg; then extra blood tests may be needed.</p><p>Curam&reg; can affect how <strong>methotrexate </strong>(a medicine used to treat cancer or rheumatic diseases) works.</p><p>Curam&reg; may affect how <strong>mycophenolate mofetil </strong>(a medicine used to prevent the rejection of transplanted organs) works.</p><p><strong>Pregnancy, breast-feeding and fertility:</strong></p><p>If your child who is about to take this medicine is pregnant or breast-feeding, thinks it may be pregnant or is planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines:</strong></p><p>Curam&reg; can have side effects and the symptoms may make you unfit to drive. Do not drive or operate machinery unless you are feeling well.</p><p>This medicine contains 8.5 mg aspartame in each dosage unit. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.</p><p>This medicine contains 0,56 mg benzyl alcohol in each dosage unit. Benzyl alcohol may cause allergic reactions. Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always give this medicine exactly as your doctor has told you. Check with your doctor or pharmacist, if you are not sure.</p><p><strong>Adults and children weighing 40 kg and over</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This suspension is not usually recommended for adults and children weighing 40 kg and over. Ask your doctor or pharmacist for advice.</p><p><strong>Children weighing less than 40 kg</strong></p><p>All doses are worked out depending on the child&rsquo;s bodyweight in kilograms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will advise you how much Curam&reg; you should give to your baby or child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be provided with a plastic measuring spoon or syringe doser. You should use this to give the correct dose to your baby or child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose &ndash; 20 mg/5 mg to 60 mg/15 mg for each kilogram of body weight a day, given in three divided doses.</p><p><strong>Patients with kidney and liver problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child has kidney problems the dose might be changed. A different strength or a different medicine may be chosen by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child has liver problems they may have more frequent blood tests to check how their liver is working.</p><p><strong>How to give Curam&reg; </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always shake the bottle well before each dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Give with a meal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Space the doses evenly during the day, at least 4 hours apart. Do not take 2 doses in 1 hour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not give your child Curam&reg; for more than 2 weeks. If your child still feels unwell they should go back to see the doctor.</p><p>&nbsp;</p><p><strong>If you give more Curam&reg; than you should</strong></p><p>If you give your child too much Curam&reg;, signs might include an upset stomach (feeling sick, being sick or diarrhoea) or convulsions. Talk to their doctor as soon as possible. Take the medicine bottle to show the doctor.</p><p>&nbsp;</p><p><strong>If you forget to give Curam&reg; </strong></p><p>If you forget to give your child a dose, give it as soon as you remember. You should not give your child the next dose too soon, but wait about 4 hours before giving the next dose. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If your child stops taking Curam&reg; </strong></p><p>Keep giving your child Curam&reg; until the treatment is finished, even if they feel better. Your child needs every dose to help fight the infection. If some bacteria survive they can cause the infection to come back.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Conditions you need to look out for Allergic reactions:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels (<em>vasculitis</em>) which may be visible as red or purple raised spots on the skin, but can affect other parts of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, joint pain, swollen glands in the neck, armpit or groin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or throat (<em>angioedema</em>), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse.</p><p><strong>Contact a doctor immediately </strong>if your child gets any of these symptoms. <strong>Stop takingCuram&reg; .</strong></p><p><strong>Inflammation of large intestine</strong></p><p>Inflammation of the large intestine, causing watery diarrhoea usually with blood and mucus, stomach pain and/or fever.</p><p><strong>Contact your doctor as soon as possible </strong>for advice if your child gets these symptoms.</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (in adults).</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrush (<em>candida </em>- a yeast infection of the vagina, mouth or skin folds)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), especially when taking high doses. If affected take Curam&reg; with a meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (in children).</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised itchy rash (<em>hives</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p>&nbsp;</p><p>Uncommon side effects that may show up in your blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in some substances (<em>enzymes</em>) produced by the liver</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge &ndash; <em>erythema multiforme)</em></p><p>if you notice any of these symptoms contact a doctor urgently.</p><p>&nbsp;</p><p>Rare side effects that may show up in your blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of cells involved in blood clotting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells</p><p>&nbsp;</p><p><strong>Frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>Other side effects have occurred in a very small number of people but their exact frequency is unknown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (see above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the large intestine (see above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the protective membrane surrounding the brain (<em>aseptic meningitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin reactions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose eyes and genitals (<em>Stevens-Johnson syndrome</em>), and a more severe form, causing extensive peeling of the skin (more than 30% of the body surface &ndash; <em>toxic epidermal necrolysis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widespread red skin rash with small pus-containing blisters (<em>bullous exfoliative dermatitis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red, scaly rash with bumps under the skin and blisters (<em>exanthemous pustulosis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms with a rash, fever, swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes) (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS))</p><p>&nbsp;</p><p><strong>Contact a doctor immediately if your child gets any of these symptoms.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice, caused by increases in the blood of bilirubin (a substance produced in the liver) which may make your child&rsquo;s skin and whites of the eyes appear yellow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of tubes in the kidney</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood takes longer to clot</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions (in people taking high doses of Curam&reg; or who have kidney problems)</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; black tongue which looks hairy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stained teeth (in children), usually removed by brushing</p><p>&nbsp;</p><p>Side effects that may show up in blood or urine tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe reduction in the number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of red blood cells (<em>haemolytic anaemia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crystals in urine.</p><p>&nbsp;</p><p><u>Reporting of side effects</u></p><p>If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet..By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 25&ordm;C. Store in the original package, in order to protect from moisture. After preparation of the ready-to-use suspension:</p><p>Store in a refrigerator (2&deg; - 8 &deg;C) and use within 7 days.</p><p>Protect from Light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are amoxicillin and clavulanic acid. Curam&reg; 125 mg/31.25 mg/5 ml powder for oral suspension</p><p>5 ml reconstituted suspension contains 125 mg amoxicillin and 31.25 mg clavulanic acid.</p><p>- The other ingredients are: Citric acid, trisodium citrate, aspartame (E951), talc, guar, silicon dioxide, lemon flavouring (contains sorbitol and glucose), peach-apricot flavouring (contains sorbitol) and orange flavouring (contains benzyl alcohol).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Curam® is an off-white powder.
After reconstitution the ready-for-use suspension is off-white.
Content of the pack:
-	Amber glass bottle 100 ml  with ring mark
-	Screw closure with sealing membranes
-	Measuring spoon (5 ml) made of polypropylene or measuring syringe (5 ml) with adapter made of polyethylene/polypropylene.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sandoz GmBH</p><p>Biochemiestrasse 10</p><p>6250 Kundl</p><p>Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">عقار كيورام<sup>&reg;</sup> هو مضاد حيوي ويعمل عن طريق قتل البكتيريا التي تُسبب العدوى. يحتوي العقار على دواءين مختلفين، هما أموكسيسيلّين وحمض الكلافيولانيك. ينتمي أموكسيسيلّين إلى مجموعة من الأدوية تُسمى &quot;البنسيلينات&quot; والتي من الممكن أحيانًا إبطال مفعولها (جعلها غير نشطة). يعمل المكون النشط الآخر (حمض الكلافيولانيك) على منع حدوث ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار كيورام<sup>&reg;</sup> في البالغين والأطفال لعلاج العدوى التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأذن الوسطى والجيوب الأنفية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة بما في ذلك عدوى الأسنان</p><p>عدوى العظام والمفاصل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تعطِ طفلك عقار كيورام</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في الحالات التَّالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يعاني من حساسية تجاه أموكسيسيلّين أو حمض الكلافيولانيك أو البنسيلين أو تجاه أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد أُصيب من قبل بتفاعل حساسية شديد تجاه أي مضاد حيوي آخر. قد يشمل هذا طفحًا جلديًّا أو تورمًا بالوجه أو الحَلْق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد عانى في أي وقتٍ بالسَّابق من مشكلات بالكبد أو من اليرقان (اصفرار الجلد) عند تناوُل أحد المضادات الحيوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تعطِ طفلك عقار كيورام</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إذا انطبق عليه أي من الوارد أعلاه</strong><strong>. </strong>إذا لم تكن متأكدًا، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل إعطاء عقار كيورام<sup>&reg;</sup></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><strong>:</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل إعطاء طفلك هذا الدَّواء في الحالات التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يُعاني من حُمّى غُدِّيَّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يخضع لعلاجٍ لمشكلات بالكبد أو بالكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لا يتبول بصفة منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت غير متأكد مما إذا كان أي مما سبق ينطبق على طفلك، تحدَّث إلى طبيبه أو الصيدلي الخاص به قبل إعطائه عقار كيورام<sup>&reg;</sup>.</p><p dir="RTL">في بعض الحالات، قد يقوم طبيبك بالتَّحقق من نوع البكتيريا التي تسبب عدوى لطفلك. بناءً على النتائج، قد يتم إعطاء طفلك تركيزًا مختلفًا من عقار كيورام<sup>&reg;</sup> أو دواءً مختلفًا.</p><p dir="RTL"><strong>الحالات التي يجب عليك التنبه لها</strong></p><p dir="RTL">قد يتسبب عقار كيورام<sup>&reg;</sup> في تفاقم بعض الحالات القائمة، أو قد يُسبب آثارًا جانبية خطيرة. تتضمن هذه الآثار تفاعلات الحساسية والتشنجات (النوبات التشنُّجية) والتهاب الأمعاء الغليظة. يجب عليك التنبه لبعض الأعراض أثناء تناوُل طفلك عقار كيورام<sup>&reg;</sup>؛ لتقليل خطر حدوث أي مشاكل. انظر <em>&quot;</em><em>الحالات التي يجب عليك التنبه لها</em><em>&quot;</em><strong> </strong>في<strong> قسم </strong><strong>4</strong>.</p><p dir="RTL"><strong>اختبارات الدَّم والبول</strong></p><p dir="RTL">إذا كان طفلك سيخضع لاختبارات دم (مثل اختبارات التَّحقق من حالة خلايا الدَّم الحمراء أو اختبارات وظائف الكبد) أو اختبارات بول (للتَّحقق من وجود الجلوكوز من عدمه)، فأعلِم الطبيب أو الممرض(ة) بأنه يتناول عقار كيورام<sup>&reg;</sup>. ذلك لأنَّ عقار كيورام<sup>&reg;</sup> قد يُؤثر على نتائج هذه الأنواع من الاختبارات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل أدوية أخرى مع عقار كيورام</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كان طفلك يتناول أو تناول مؤخرًا أو قد يتناول أيَّة أدوية أخرى. يشمل ذلك الأدوية التي يُمكِن شراؤها بدون وصفة طبية والأدوية العشبية.</p><p dir="RTL">إذا كان طفلك يتناول <strong>ألوبيورينول</strong> (يُستَخدَم لعلاج النّقْرس) مع عقار كيورام<sup>&reg;</sup>، فقد يكون أكثر عُرضة للإصابة بتفاعل حساسية جلدي.</p><p dir="RTL">إذا كان طفلك يتناول <strong>بروبنيسيد</strong> (يُستَخدَم لعلاج النّقْرس)، فقد يقرر الطبيب تعديل جرعة عقار كيورام<sup>&reg;</sup>.</p><p dir="RTL">إذا تم تناوُل الأدوية التي تُساعد على منع الجلطات الدَّموية (مثل <strong>وارفارين</strong>) مع عقار كيورام<sup>&reg;</sup>، فقد يتطلب الأمر إجراء اختبارات دم إضافية.</p><p dir="RTL">يُمكِن لعقار كيورام<sup>&reg;</sup> أن يُؤثر على كيفية عمل <strong>ميثوتريكسات </strong>(دواء يُستَخدَم لعلاج السرطان أو الأمراض الروماتيزمية).</p><p dir="RTL">قد يُؤثر عقار كيورام<sup>&reg;</sup> على كيفية عمل <strong>مَيكوفينوليت موفيتيل </strong>(دواء يُستَخدَم لمنع رفض الجسم للأعضاء المزروعة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong><strong>:</strong></p><p dir="RTL">إذا كانت طفلتك الموشِكة على تناول هذا الدَّواء حاملًا أو مرضعًا، أو تعتقد أنها قد تكون حاملًا أو تُخطط لذلك، فاستشِر الطبيب أو الصيدلي قبل أن يتم تناوُل هذا الدَّواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><strong>:</strong></p><p dir="RTL">قد يكون لعقار كيورام<sup>&reg;</sup> آثار جانبية، وقد تجعلك الأعراض غير مؤهل للقيادة. لا تقُم بالقيادة أو بتشغيل الآلات إلا إذا كنت تشعر بأنك على ما يُرام.</p><p dir="RTL">يحتوي هذا الدَّواء على 8.5 مجم من الأسبارتام في كل وحدة جرعة. أسبارتام هو مصدرٌ للفينيل ألانين. قد يكون مضرًّا إذا كنت تُعاني من بيلة الفينيل كيتون، وهو اضطراب وراثي نادر يتراكم فيه الفينيل ألانين بسبب عدم قدرة الجسم على إزالته بشكل سليم.</p><p dir="RTL">يحتوي هذا الدَّواء على 0.56 مجم من الكحول البنزيلي في كل وحدة جرعة. قد يُسبب الكحول البنزيلي تفاعلات حساسية. استشر طبيبك أو الصيدلي الخاص بك إذا كنت تُعاني من مرض بالكبد أو الكُلى. ذلك لأنَّ الكميات الكبيرة من الكحول البنزيلي يُمكِن أن تتراكم في جسمك وقد تتسبب في حدوث آثار جانبية (ما يُسمى بـ&quot;الحُماض الاستقلابي&quot;).</p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناوُل هذا المنتج الدَّوائي.</p><p>يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل وحدة جرعة، وهو ما يعني أنه &quot;خال من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائمًا بإعطاء هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL"><strong>البالغون والأطفال الذين تبلغ أوزانهم </strong><strong>40 </strong><strong>كجم فأكثر</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا المُعلَّق لا يُوصى به عادةً للبالغين والأطفال ممن تبلغ أوزانهم 40 كجم فأكثر. اطلب المشورة من طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL"><strong>الأطفال البالغ وزنهم أقل من </strong><strong>40 </strong><strong>كجم</strong></p><p dir="RTL">تتم معايرة كل الجرعات اعتمادًا على وزن جسم الطفل بالكيلوجرام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سينصحك طبيبك بالكمية التي عليك أن تعطيها لصغيرك أو طفلك من عقار كيورام&reg; .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم تزويدك بملعقة قياس بلاستيكية أو سرنجة مُحدِّدة للجرعات. يجب عليك استخدام هذه الأداة؛ لإعطاء الجرعة الصحيحة لصغيرك أو طفلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها هي - 20 مجم/5 مجم إلى 60 مجم/15 مجم لكل كيلوجرام من وزن الجسم في اليوم، تُعطى في ثلاث جرعات مُقَسَّمة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المرضى الذين يعانون من مشكلات بالكلى والكبد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يُعاني من مشاكل في الكُلى فقد يتم تغيير الجرعة. قد يختار طبيبك تركيزًا مختلفًا أو دواءً مختلفًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يُعاني من مشاكل في الكبد فقد يتوجب عمل اختبارات دم بشكلٍ أكثر تكرارًا؛ للتَّحقق من كيفية عمل الكبد لديه.</p><p dir="RTL"><strong>كيفية إعطاء عقار كيورام</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُم برَج الزجاجة بشكل جيد قبل كل جرعة دومًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعطى مع الوجبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك فواصل زمنية متساوية بين الجرعات خلال اليوم؛ بحيث لا تقل عن 4 ساعات. لا تُعطِ جرعتين في ساعة واحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تعطِ طفلك عقار كيورام<sup>&reg;</sup> لأكثر من أسبوعين. إذا كان طفلك لا يزال يشعر بالتوعُّك، فعليه العودة لرؤية الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا أعطيت كمية أكثر مما يجب من عقار كيورام</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">إذا أعطيت طفلك كمية أكثر من اللازم من عقار كيورام<sup>&reg;</sup> ، فقد تشمل العلامات تهيُّج المعدة (شعورًا بالإعياء أو إصابة بالإعياء أو إسهالًا) أو تشنُّجات. تحدَّث مع طبيبه في أسرع وقت ممكن. خذ معك زجاجة الدَّواء؛ ليطلع عليها الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت إعطاء عقار كيورام</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">إذا أغفلت إعطاء إحدى الجرعات لطفلك، فقُم بإعطائه إياها بمجرد أن تتذكر. يجب ألا تعطي طفلك الجرعة التَّالية في وقتٍ قريب، ولكن انتظر 4 ساعات قبل إعطاء الجرعة التَّالية. لا تُعطِ جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>إذا توقف طفلك عن تناوُل عقار كيورام</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">استمر في إعطاء طفلك عقار كيورام<sup>&reg;</sup> حتى انتهاء العلاج، حتى إذا شعر بتحسُّن. طفلك بحاجة إلى كل جرعة؛ للمساعدة في مكافحة العدوى. إذا نجت بعض البكتيريا فقد تسبب عودة العدوى.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>الحالات التي يجب عليك التنبه لها لحدوث تفاعلات حساسية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>التهاب الأوعية الدَّموية</em> الذي قد يظهر على هيئة بقع على الجلد، بارزة، حمراء أو أرجوانية، ولكن قد يُصيب أجزاء أخرى من الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى وألم بالمفاصل وتورُّم بالغدد في الرقبة أو الإبط أو الفخذ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم، يصيب في بعض الأحيان الوجه أو الحَلْق (<em>وذمة وعائية</em>)، مما يُسبب صعوبة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط.</p><p dir="RTL"><strong>اتصل بطبيبٍ فورًا</strong> إذا أُصيب طفلك بأي من هذه الأعراض. <strong>توقف عن إعطاء عقار كيورام</strong><strong>&reg;.</strong></p><p dir="RTL"><strong>التهاب الأمعاء الغليظة</strong></p><p dir="RTL">التهاب الأمعاء الغليظة، وهو ما ينجم عنه الإصابة بإسهال مائي يكون عادةً مصحوبًا بدم ومخاط، ألم بالمعدة و/أو حُمّى.</p><p dir="RTL"><strong>اتصل بطبيبك في أسرع وقت ممكن؛ </strong>لتلقي المشورة إذا أُصيب طفلك بهذه الأعراض.</p><p dir="RTL"><strong>الآثار الجانبية الشَّائعة جدًّا</strong> (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال (في البالغين).</p><p dir="RTL"><strong>الآثار الجانبية الشَّائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُلَاق (<em>فطر الكانديدا </em><em>- </em>وهي<em> </em>عدوى فطرية تصيب المهبل أو الفم أو ثنايا الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (غثيان)، لا سيَّما عند تناوُل جرعات مرتفعة. إذا تأثَّر طفلك بذلك فأعطهِ عقار كيورام&reg; مع وجبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال (في الأطفال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بارز مثير للحكة (<em>شرى</em>).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> التي قد تظهر في اختبارات الدَّم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في بعض المواد (<em>الإنزيمات</em>) التي يفرزها الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النَّادرة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>طفح جلدي قد يتحول إلى بثور ويبدو مثل أهدافٍ صغيرة (بقع داكنة مركزية محاطة بمنطقة أكثر شحوبًا، مع وجود حلقة داكنة حول الحافة - <em>احمرار متعدد الأشكال</em>).</p><p dir="RTL">إذا لاحظت أيًّا من هذه الأعراض فتحدث إلى طبيبٍ بشكلٍ عاجل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النَّادرة</strong> التي قد تظهر في اختبارات الدَّم لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الخلايا المشاركة في عملية تجلط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم البيضاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة التكرار</strong> (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">لُوحظ حدوث آثار جانبية أخرى في عدد قليل للغاية من الأشخاص، ولكن معدّل تكرارها الدّقيق غير معروف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (انظر أعلاه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة (انظر أعلاه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية الواقية المحيطة بالمخ (<em>التهاب السحايا غير الصديدي</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية خطيرة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار مع بثور وتقشُّر بالجلد، لا سيَّما حول الفم والأنف والعينين والأعضاء التناسلية (<em>متلازمة ستيفنز جونسون</em>)، وشكل آخر أكثر شدة، يسبب تقشرًا واسع النطاق بالجلد (أكثر من 30٪ من سطح الجسم - <em>انحلال البشرة النخري التَّسَمُّمِيّ</em>).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر واسع النطاق مع بثور صغيرة تحتوي على صديد (<em>التهاب الجلد التقشري الفقاعي</em>).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر تقشري مع وجود كتل أسفل الجلد وبثور (<em>بُثار طفحي</em>).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بأعراض الأنفلونزا مصحوبة بطفح جلدي وحُمَّى وتورُّم بالغدد ونتائج غير طبيعية لاختبارات الدَّم [بما في ذلك زيادة عدد خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات) وإنزيمات الكبد] (الطفح الجلدي الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية DRESS).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بطبيبٍ فورًا إذا أُصيب طفلك بأي من هذه الأعراض</strong><strong>.</strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>التهاب الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان، يحدث بفعل ارتفاع مستوى البيليروبين في الدَّم (مادة تُفرز في الكبد)، مما قد يجعل جلد طفلك وبياض عينيه يبدوان بلون أصفر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنابيب الموجودة بالكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استغراق الدَّم فترة أطول ليتجلَّط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات (في الأشخاص الذين يتناولون جرعات مرتفعة من عقار كيورام&reg; أو الذين يعانون من مشكلات بالكُلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لسان أسود يبدو مشعرًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصبُّغ الأسنان (في الأطفال)، وعادةً ما يزول عن طريق تنظيف الأسنان بالفرشاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية التي قد تظهر في اختبارات الدَّم أو البول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في عدد خلايا الدَّم البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم الحمراء (<em>فقر الدَّم الانحلالي</em><em>).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بلورات في البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الإبلاغ عن الآثار الجانبية</u></p><p dir="RTL">إذا ظهرت لدى طفلك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكارتونية وعلى الزجاجة بعد كلمة EXP. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا يخزن في درجة حرارة تتعدى 25 درجة مئوية. يجب حفظ الدَّواء في العبوة الأصلية لحمايته من الرطوبة. بعد إعداد المُعلَّق الجاهز للاستخدام:</p><p dir="RTL">يُحفَظ في الثلاجة (2 - 8 درجة مئوية) ويُستَخدَم خلال 7 أيام.</p><p dir="RTL">يُحفَظ بعيدًا عن الضوء.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي أموكسيسيلّين وحمض الكلافيولانيك. كيورام<sup>&reg;</sup> <strong>١٥٦،٢٥</strong> مجم / <strong>ﻞﻣ ٥</strong> مسحوق لإعداد معلق فموي.</p><p dir="RTL">يحتوي كل 5 مللي لتر من المُعلَّق المُعَد على 125 مجم أموكسيسيلين و 31.25 مجم حمض الكلافيولانيك.</p><p dir="RTL">-المكونات الأخرى هي: حمض الستريك، سترات ثلاثي الصوديوم، أسبارتام (E951)، تَلْك، غوار، ثاني أكسيد السيليكون، نكهة الليمون (تحتوي على سوربيتول وجلوكوز)، نكهة الخوخ والمشمش (تحتوي على سوربيتول) ونكهة البرتقال (تحتوي على كحول بنزيلي).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار كيورام<sup>&reg;</sup> عبارة عن مسحوق أبيض مائل إلى الصُّفرة.</p><p dir="RTL">بعد الإعداد يُصبح المُعلَّق الجاهز للاستخدام أبيض مائلًا إلى الصُّفرة.</p><p dir="RTL"><strong>محتويات العبوة</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زجاجة من الزجاج الكهرماني، بحجم 100 مللي لتر مع علامة حلقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غالق لولبي مع أغشية عازلة</p><p>ملعقة قياس (5 مللي لتر) مصنوعة من البولي بروبيلين أو سرنجة قياس (5 مللي لتر) مع مُوائِم مصنوع من البولي إيثيلين/ البولي بروبيلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة ساندوز المحدودة</p><p dir="RTL">10 شارع بيوشيمي</p><p dir="RTL">6250 كوندل</p><p dir="RTL">النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Curam® 156.25 mg / 5 ml powder for oral suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 25 mg amoxicillin (as amoxicillin trihydrate) and 6.25 mg clavulanic acid (as potassium clavulanate).


Excipients with known effect:
Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 1.7 mg aspartame. Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.019 mmol (0.44 mg) sodium.
Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.21 mg glucose. Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.03 mg sorbitol.
Each ml reconstituted suspension (corresponding to 0.09 g powder) contains 0.11 mg benzyl alcohol.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for oral suspension 
Off-white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Curam&reg; is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial sinusitis (adequately diagnosed)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute otitis media</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community acquired pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cystitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyelonephritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone and joint infections, in particular osteomyelitis.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.</p><p>&nbsp;</p><p>The dose of Curam&reg; that is selected to treat an individual infection should take into account:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The severity and the site of the infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The age, weight and renal function of the patient as shown below.</p><p>&nbsp;</p><p>The use of alternative presentations of Curam&reg; (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>For adults and children &sup3; 40 kg, this formulation of Curam&reg; provides a total daily dose of 1500 mg amoxicillin/375 mg clavulanic acid, when administered as recommended below. For children &lt; 40 kg, this formulation of Curam&reg; provides a maximum daily dose of 2400 mg amoxicillin/600 mg clavulanic acid, when administered as recommended below. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that another</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>preparation of Curam&reg; is selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review (see section 4.4 regarding prolonged therapy).</p><p>&nbsp;</p><p><u>Adults and children </u><u>&sup3; 40 kg</u></p><p>One 500 mg/125 mg dose taken three times a day.</p><p>&nbsp;</p><p><u>Children &lt; 40 kg</u></p><p>20 mg/5 mg/kg/day to 60 mg/15 mg/kg/day given in three divided doses.</p><p>&nbsp;</p><p>Children may be treated with Curam&reg; tablets, suspensions or paediatric sachets. Children aged 6 years and below should preferably be treated with Curam&reg; suspension or paediatric sachets.</p><p>&nbsp;</p><p>No clinical data are available on doses of Curam&reg; 4:1 formulations higher than 40 mg/10 mg/kg per day in children under 2 years.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>No dose adjustment is considered necessary.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Dose adjustments are based on the maximum recommended level of amoxicillin.</p><p>No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.</p><p>&nbsp;</p><p><em>Adults and children </em>&sup3; <em>40 kg</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CrCl: 10-30</p><p>ml/min</p></td><td style="vertical-align:top"><p>500 mg/125 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>CrCl &lt; 10 ml</p><p>/min</p></td><td style="vertical-align:top"><p>500 mg/125 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>500 mg/125 mg every 24 hours, plus 500 mg/125 mg during dialysis, to be repeated at the end of dialysis (as serum concentrations of both amoxicillin and clavulanic acid are decreased)</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Children &lt; 40 kg</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CrCl: 10-30</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg twice daily (maximum 500 mg/125 mg twice daily).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>ml/min</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CrCl &lt; 10 ml</p><p>/min</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg as a single daily dose (maximum 500 mg/125 mg).</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg per day once daily.</p><p>Prior to haemodialysis 15 mg/3.75 mg/kg. In order to restore circulating drug levels, 15 mg/3.75 mg per kg should be administered after haemodialysis.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><u>Hepatic impairment</u></p><p>Dose with caution and monitor hepatic function at regular intervals (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Method&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; administration </u>Curam&reg; is for oral use.</p><p>&nbsp;</p><p>Curam&reg; should be administered with a meal to minimise potential gastrointestinal intolerance.</p><p>&nbsp;</p><p>Therapy can be started parenterally according the SPC of the IV-formulation and continued with an oral preparation.</p><p>&nbsp;</p><p>Shake to loosen powder, add water as directed, invert and shake. Shake the bottle before each dose (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients listed in section 6.1.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid (see section 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.</p><p>&nbsp;</p><p>In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.</p><p>&nbsp;</p><p>This presentation of Curam&reg; is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid.&nbsp; This presentation should not be used to treat penicillin-resistant <em>S. pneumoniae</em>.</p><p>&nbsp;</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses (see section 4.8).</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.</p><p>&nbsp;</p><p>Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.</p><p>&nbsp;</p><p>Prolonged use may occasionally result in overgrowth of non-susceptible organisms.</p><p>&nbsp;</p><p>The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP) (see Section 4.8). This reaction requires Curam&reg; discontinuation and contra-indicates any subsequent administration of amoxicillin.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment (see sections 4.2, 4.3 and 4.8).</p><p>&nbsp;</p><p>Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment.&nbsp; These events have been very rarely reported in children.&nbsp; In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and, in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects (see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Antibiotic-associated colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening (see section 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contra-indicated in this situation.</p><p>&nbsp;</p><p>Periodic assessment of organ system functions, including renal, hepatic and haematopoietic function is advisable during prolonged therapy.</p><p>&nbsp;</p><p>Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see section 4.5 and 4.8).</p><p>&nbsp;</p><p>In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see section 4.2).</p><p>&nbsp;</p><p>In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see section 4.9).</p><p>&nbsp;</p><p>During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non- enzymatic methods.</p><p>&nbsp;</p><p>The presence of Clavulanic acid in Curam&reg; may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.</p><p>&nbsp;</p><p>There have been reports of positive test results using the Bio-Rad Laboratories Platelia <em>Aspergillus </em>EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of <em>Aspergillus </em>infection. Cross-reactions with non-<em>Aspergillus </em>polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia <em>Aspergillus </em>EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; Curam&reg; contains 1.7 mg of aspartame (E951) per ml, a source of phenylalanine. This medicine &nbsp;&nbsp;should be used with caution in patients with phenylketonuria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Oral anticoagulants</u></p><p>Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co- administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</p><p>&nbsp;</p><p><u>Probenecid</u></p><p>Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.</p><p>&nbsp;</p><p><u>Mycophenolate mofetil</u></p><p>In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure.</p><p>Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Breast-feeding</u></p><p>Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. The possibility</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>of sensitisation should be taken into account. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.</p><p>&nbsp;</p><p>The ADRs derived from clinical studies and post-marketing surveillance with Curam&reg;, sorted by MedDRA System Organ Class are listed below.</p><p>&nbsp;</p><p>The following terminologies have been used in order to classify the occurrence of undesirable effects. Very common (&sup3;1/10)</p><p>Common (&sup3;1/100 to &lt;1/10) Uncommon (&sup3;1/1,000 to &lt;1/100) Rare (&sup3;1/10,000 to &lt;1/1,000) Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mucocutaneous candidosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Overgrowth of non-susceptible organisms</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Reversible leucopenia (including neutropenia)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Reversible agranulocytosis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Prolongation of bleeding time and prothrombin time1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong><strong>10</strong></p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylaxis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Serum sickness-like syndrome</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity vasculitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reversible hyperactivity</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions2</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Aseptic meningitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea3</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Indigestion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Antibiotic-associated colitis4</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Black hairy tongue</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Tooth discolouration11</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rises in AST and/or ALT5</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis6</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Cholestatic jaundice6</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong>7</p></td></tr><tr><td style="vertical-align:top"><p>Skin rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Bullous exfoliative-dermatitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Acute generalised exanthemous pustulosis (AGEP)9</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Crystalluria8</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>1&nbsp; See section 4.4</p><p>2&nbsp; See section 4.4</p><p>3&nbsp; Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking Curam&reg; with a meal.</p><p>4&nbsp; Including pseudomembranous colitis and haemorrhagic colitis (see section 4.4)</p><p>5&nbsp; A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown.</p><p>6&nbsp;&nbsp; These events have been noted with other penicillins and cephalosporins (see section 4.4).</p><p>7&nbsp; If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued (see section 4.4).</p><p>8&nbsp; See section 4.9</p><p>9&nbsp; See section 4.4</p><p>10&nbsp; See sections 4.3 and 4.4</p><p>11&nbsp; Superficial tooth discolouration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs of overdose</u></p><p>Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see section 4.4).</p><p>&nbsp;</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses.</p><p>&nbsp;</p><p>Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses.&nbsp; A regular check of patency should be maintained (see section 4.4).</p><p>&nbsp;</p><p><u>Treatment of intoxication</u></p><p>Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CR02.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.</p><p>&nbsp;</p><p>Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.</p><p>&nbsp;</p><p>Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.</p><p>&nbsp;</p><p><u>PK/PD relationship</u></p><p>The time above the minimum inhibitory concentration (T&gt;MIC) is considered to be the major determinant of efficacy for amoxicillin.</p><p>&nbsp;</p><p><u>Mechanisms of resistance</u></p><p>The two main mechanisms of resistance to amoxicillin/clavulanic acid are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.</p><p>&nbsp;</p><p>Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>MIC breakpoints for amoxicillin/clavulanic acid are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Organism</p></td><td colspan="3" style="vertical-align:top"><p>Susceptibility Breakpoints (&micro;g/ml)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Intermediate</p></td><td style="vertical-align:top"><p>Resistant</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em><strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 1</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em><strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 1</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em><strong>2</strong></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci <strong>2</strong></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus</em><strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus A, B, C, G</em><strong>5</strong></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em><strong>3</strong></p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>1-2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriaceae<strong>1,4</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative Anaerobes<strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive Anaerobes<strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<strong>1</strong></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>4-8</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>1&nbsp; The reported values are for Amoxicillin concentrations. For susceptibility testing purposes, the concentration of Clavulanic acid is fixed at 2 mg/l.</p><p>2&nbsp; The reported values are Oxacillin concentrations.</p><p>3&nbsp; Breakpoint values in the table are based on Ampicillin breakpoints.</p><p>4&nbsp; The resistant breakpoint of R&gt;8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.</p><p>5&nbsp; Breakpoint values in the table are based on Benzylpenicillin breakpoints.</p></td></tr></tbody></table><p>&nbsp;</p><p>The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p><!--[if gte vml 1]><o:wrapblock
 pagebreak="t">
 <v:group id="Group_x0020_12" o:spid="_x0000_s1034" style='position:absolute;
  margin-left:79.2pt;margin-top:12.45pt;width:464.9pt;height:68.9pt;z-index:1096;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1584,249" coordsize="9298,1378"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_19" o:spid="_x0000_s1035" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,271" to="10862,271"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_18" o:spid="_x0000_s1036" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,549" to="10862,549"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_17" o:spid="_x0000_s1037" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1595,260" to="1595,1616"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_16" o:spid="_x0000_s1038" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,1605" to="10862,1605"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_15" o:spid="_x0000_s1039" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="10871,260" to="10871,1616"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.08pt"/>
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_14" o:spid="_x0000_s1040"
   type="#_x0000_t202" style='position:absolute;left:1595;top:271;width:9276;
   height:279;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
   o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'>Commonly susceptible species<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_13" o:spid="_x0000_s1041" type="#_x0000_t202"
   style='position:absolute;left:1595;top:549;width:9276;height:1056;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'><u>Aerobic Gram-positive
      micro-organisms</u><o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.3pt;margin-right:5.0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:101%'><i
      style='mso-bidi-font-style:normal'>Enterococcus faecalis Gardnerella
      vaginalis<o:p></o:p></i></p>
      <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'><i style='mso-bidi-font-style:
      normal'>Staphylococcus aureus (</i>methicillin-susceptible)£<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="621" height="93" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci (methicillin-susceptible)</p><p><em>Streptococcus agalactiae Streptococcus pneumoniae</em>1</p><p><em>Streptococcus pyogenes </em>and other beta-haemolytic streptococci</p><p><em>Streptococcus viridans </em>group</p><p>&nbsp;</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Capnocytophaga </em>spp. <em>Eikenella corrodens Haemophilus influenzae</em>2 <em>Moraxella catarrhalis Pasteurella multocida</em></p><p>&nbsp;</p><p><u>Anaerobic micro-organisms </u><em>Bacteroides fragilis Fusobacterium nucleatum Prevotella </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p>Species for which acquired resistance may be a problem</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecium </em>$</p><p>&nbsp;</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Proteus vulgaris</em></p></td></tr><tr><td style="vertical-align:top"><p>Inherently resistant organisms</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter </em>sp. <em>Citrobacter freundii Enterobacter </em>sp.</p><p><em>Legionella pneumophila Morganella morganii Providencia </em>spp.</p><p><em>Pseudomonas </em>sp.</p><p><em>Serratia </em>sp.</p><p><em>Stenotrophomonas maltophilia</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_4" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:79.2pt;margin-top:15.5pt;width:464.9pt;height:172.6pt;z-index:1168;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1584,310" coordsize="9298,3452"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_11" o:spid="_x0000_s1027" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,332" to="10862,332"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_10" o:spid="_x0000_s1028" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,2166" to="10862,2166"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_9" o:spid="_x0000_s1029" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1595,321" to="1595,3751"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_8" o:spid="_x0000_s1030" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1603,3740" to="10862,3740"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:line id="Line_x0020_7" o:spid="_x0000_s1031" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="10871,321" to="10871,3751"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.08pt"/>
  <v:shape id="Text_x0020_Box_x0020_6" o:spid="_x0000_s1032" type="#_x0000_t202"
   style='position:absolute;left:1595;top:332;width:9276;height:1834;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDWKgUqwgAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvwv6H8Ba8aaoH0a5RRFYQBLHWg8e3zbMNNi/dJmr990ZY2OMwM98w82Vna3Gn1hvHCkbDBARx
4bThUsEp3wymIHxA1lg7JgVP8rBcfPTmmGr34Izux1CKCGGfooIqhCaV0hcVWfRD1xBH7+JaiyHK
tpS6xUeE21qOk2QiLRqOCxU2tK6ouB5vVsHqzNm3+d3/HLJLZvJ8lvBuclWq/9mtvkAE6sJ/+K+9
1Qpm8L4Sb4BcvAAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDWKgUqwgAAANoAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.2pt'><span style='font-size:11.5pt;
      mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
      <p class=MsoNormal style='margin-top:0in;margin-right:333.15pt;
      margin-bottom:0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:
      101%'><u>Other micro-organisms </u><i style='mso-bidi-font-style:normal'>Chlamydophila
      pneumoniae Chlamydophila psittaci Coxiella burnetti Mycoplasma pneumoniae<o:p></o:p></i></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1033" type="#_x0000_t202"
   style='position:absolute;left:1595;top:2166;width:9276;height:1575;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt'>$ Natural intermediate
      susceptibility in the absence of acquired mechanism of resistance.<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.3pt;margin-right:0in;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:12.15pt;
      mso-line-height-rule:exactly'>£All methicillin-resistant staphylococci
      are resistant to amoxicillin/clavulanic acid<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:.65pt;margin-right:8.25pt;
      margin-bottom:0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:
      13.0pt;mso-line-height-rule:exactly'><span style='font-size:7.0pt;
      mso-bidi-font-size:11.0pt;position:relative;top:-5.0pt;mso-text-raise:
      5.0pt'>1</span><i style='mso-bidi-font-style:normal'>Streptococcus
      pneumoniae </i>that are resistant to penicillin should not be treated with
      this presentation of amoxicillin/clavulanic acid (see sections 4.2 and
      4.4).<o:p></o:p></p>
      <p class=MsoNormal style='margin-top:0in;margin-right:8.25pt;margin-bottom:
      0in;margin-left:5.3pt;margin-bottom:.0001pt;line-height:13.0pt;
      mso-line-height-rule:exactly'><span style='font-size:7.0pt;mso-bidi-font-size:
      11.0pt;position:relative;top:-5.0pt;mso-text-raise:5.0pt'>2 </span>Strains
      with decreased susceptibility have been reported in some countries in the
      EU with a frequency higher than 10%.<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Other micro-organisms </u><em>Chlamydophila pneumoniae Chlamydophila psittaci Coxiella burnetti Mycoplasma pneumoniae</em></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>$ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.</p><p>&pound;All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid</p><p>1<em>Streptococcus pneumoniae </em>that are resistant to penicillin should not be treated with this presentation of amoxicillin/clavulanic acid (see sections 4.2 and 4.4).</p><p>2 Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Amoxicillin and clavulanic acid, are fully dissociated in aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral route of administration. Absorption of amoxicillin/clavulanic acid is optimised when taken at the start of a meal. Following oral administration, amoxicillin and clavulanic acid are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (Tmax) in each case is approximately one hour.</p><p>&nbsp;</p><p>The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (500 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers are presented below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Mean (&plusmn; SD) pharmacokinetic parameters</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Active substance(s) administered</p></td><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>Tmax *</p></td><td style="vertical-align:top"><p>AUC (0-24h)</p></td><td style="vertical-align:top"><p>T 1/2</p></td></tr><tr><td style="vertical-align:top"><p>(mg)</p></td><td style="vertical-align:top"><p>(&micro;g/ml)</p></td><td style="vertical-align:top"><p>(h)</p></td><td style="vertical-align:top"><p>(&micro;g.h/ml)</p></td><td style="vertical-align:top"><p>(h)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Amoxicillin</p></td></tr><tr><td style="vertical-align:top"><p>AMX/CA</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>7.19</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>53.5</p></td><td style="vertical-align:top"><p>1.15</p></td></tr><tr><td style="vertical-align:top"><p>500/125 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&plusmn; 2.26</p></td><td style="vertical-align:top"><p>(1.0-2.5)</p></td><td style="vertical-align:top"><p>&plusmn; 8.87</p></td><td style="vertical-align:top"><p>&plusmn; 0.20</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Clavulanic acid</p></td></tr><tr><td style="vertical-align:top"><p>AMX/CA</p><p>500 mg/125 mg</p></td><td style="vertical-align:top"><p>125</p></td><td style="vertical-align:top"><p>2.40</p><p>&plusmn; 0.83</p></td><td style="vertical-align:top"><p>1.5</p><p>(1.0-2.0)</p></td><td style="vertical-align:top"><p>15.72 &plusmn; 3.86</p></td><td style="vertical-align:top"><p>0.98 &plusmn;</p><p>0.12</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:108.05pt;
  margin-top:16.6pt;width:371.9pt;height:28.45pt;z-index:1192;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1.08pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:4.8pt;line-height:12.6pt;
     mso-line-height-rule:exactly'>AMX – amoxicillin, CA – clavulanic acid<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.3pt;margin-right:0in;margin-bottom:
     0in;margin-left:4.8pt;margin-bottom:.0001pt'>* Median (range)<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="500" height="43" alt="Text Box: AMX – amoxicillin, CA – clavulanic acid
* Median (range)
" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid.</p><p>&nbsp;</p><p>Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus.</p><p>Amoxicillin does not adequately distribute into the cerebrospinal fluid.</p><p>&nbsp;</p><p>From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk (see section 4.6).</p><p>Both amoxicillin and clavulanic acid have been shown to cross the placental barrier (see section 4.6). <u>Biotransformation</u></p><p>Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to</p><p>up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of single Curam&reg; 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid (see section 4.5).</p><p>&nbsp;</p><p><u>Age</u></p><p>The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted <em>via </em>the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.</p><p>&nbsp;</p><p>Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.</p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with Curam&reg; or its components.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid Trisodium citrate</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Aspartame (E951) Talc</p><p>Guar</p><p>Silicon dioxide</p><p>Lemon flavouring (contains glucose and sorbitol) Peach-apricot flavouring (contains sorbitol) Orange flavouring (contains benzyl alcohol)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
The reconstituted suspension is stable for 7 days when stored at 2-8 °C

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder for oral suspension: Do not store above 25 &deg;C. Store in the original package, in order to&nbsp; protect from moisture.</p><p>&nbsp;</p><p>Protect from light.</p><p>&nbsp;</p><p>The reconstituted suspension should be stored in a refrigerator (2&deg; - 8 &deg;C) and used within 7 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Curam&reg; 125 mg/31.25 mg/5 ml powder for oral suspension The primary packaging materials consists of</p><p>-&nbsp; Amber glass bottle 100 ml&nbsp; with ring mark</p><p>-&nbsp; Screw closure with sealing membranes</p><p>-&nbsp; Measuring spoon (5 ml) made of polypropylene or measuring syringe (5 ml) with adapter made of polyethylene/polypropylene.</p><p>&nbsp;</p><p>1 bottle of 9 g powder (for preparing 100 ml suspension)</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Check cap seal is intact before using. Shake bottle to loosen powder. Add volume of water (as indicated below) invert and shake well. Alternatively fill the bottle with water to just below the ring mark on bottle label, invert and shake well, then top up with water exactly to the ring mark, invert and again shake well.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Strength</strong></p></td><td style="vertical-align:top"><p><strong>Volume of water to be added at reconstitution (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Final volume of reconstituted oral suspension (ml)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>125 mg/31.25 mg/5 ml</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>71.25</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>114</p></td><td style="vertical-align:top"><p>120</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>250 mg/62.5 mg/5 ml</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>67.5</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>120</p></td></tr></tbody></table><p>&nbsp;</p><p>Shake the bottle well before each dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>After reconstitution the ready-for-use suspension is off-white.</p><p>&nbsp;</p><p>This medicinal product should not be used if lumps of powder are still visible in the bottle before reconstitution.</p><p>After reconstitution the product should not be used if the colour of the reconstituted product is different from the one described before.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmBH
Biochemiestrasse 10
6250 Kundl
Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>